Dr. Batchelor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Brigham and Women's Hospital
Hale Building, 4th Floor, 60 Fenwood Road
Boston, MA 02115Phone+1 617-732-5355
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1991 - 1994
- Yale-New Haven Medical CenterInternship, Internal Medicine, 1990 - 1991
- Emory University School of MedicineClass of 1990
Certifications & Licensure
- MA State Medical License 1995 - 2026
- FL State Medical License 2015 - 2017
- NY State Medical License 1994 - 2001
- NJ State Medical License 1995 - 1997
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2012-2020
- Boston Magazine Castle Connolly, 2011-2020
- America's Top Doctors for Cancer Castle Connolly, 2011-2020
- Join now to see all
Publications & Presentations
PubMed
- 32 citationsTumor inflammation-associated neurotoxicity.Jasia Mahdi, Jorg Dietrich, Karin Straathof, Claire Roddie, Brian J Scott
Nature Medicine. 2023-04-01 - 33 citationsPhase I trial of sorafenib in patients with recurrent or progressive malignant glioma.Louis B. Nabors, Jeffrey G. Supko, Myrna R. Rosenfeld, Marc C. Chamberlain, Surasak Phuphanich
Neuro-Oncology. 2011-12-01 - 1235 citationsAn Integrative Model of Cellular States, Plasticity, and Genetics for GlioblastomaCyril Neftel, Julie Laffy, Mariella G. Filbin, Toshiro Hara, Marni E. Shore
Cell. 2019-08-08
Journal Articles
- Phase I and Biomarker Study of Plerixafor and Bevacizumab in Recurrent High-Grade GliomaElizabeth Gerstner, Rakesh K Jain, Tracy Batchelor, Clinical Cancer Research
- Primary Central Nervous System LymphomaTracy Batchelor, MD, Seminars in Neurology
Press Mentions
- Vulnerability in Brain Tumors May Open Door to New TreatmentsSeptember 26th, 2022
- Regulus Therapeutics Inc (NASDAQ: RGLS) Will Start a Trial for miR-155April 8th, 2022
- New Thinking About What's Fueling Glioma Growth Hint It's in the SynapsesOctober 17th, 2019
- Join now to see all
Grant Support
- Training Program In Nervous System TumorsNational Cancer Institute2008–2011
- Clinical And Molecular Studies Of Novel Therapeutics In Malignant Brain TumorsNational Cancer Institute2007–2011
- Azd2171 And Chemoradiation For Newly Diagnosed GlioblastomaNational Cancer Institute2007–2011
- Annual Primary CNS Lymphoma Collaborative Group MeetingNational Cancer Institute2006–2010
- Clinical Trial: A Phase 2 Study Of Azd2171 In Recurrent Glioblastoma (Nci ProtocNational Center For Research Resources2008
- Nabtt-New Approaches To Brain Tumor Therapy (CNSC)National Cancer Institute2004–2008
- A Phase 2 Study Of Azd2171 In Recurrent Glioblastoma (Nci Protocol #7105)National Center For Research Resources2007
- A Phase 2 Study Of Azd2171 In Recurrent GlioblastomaNational Cancer Institute2005–2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: